Wenhui H. Li

Kunming, 650118, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

COX7A2L drives lung adenocarcinoma progression and radioresistance via PI3K/AKT signaling.

COX7A2L drives lung adenocarcinoma progression and radioresistance via PI3K/AKT signaling.

Journal: Life sciences

Published: February 25, 2026

Local global feature enhanced transformer with attention pruning for precise medical image segmentation.

Local global feature enhanced transformer with attention pruning for precise medical image segmentation.

Journal: iScience

Published: October 09, 2025

ZIP10 drives radioresistance and malignant progression in lung adenocarcinoma by inhibiting the Hippo pathway via a Zinc-LATS axis.

ZIP10 drives radioresistance and malignant progression in lung adenocarcinoma by inhibiting the Hippo pathway via a Zinc-LATS axis.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 15, 2025

Integrative stemness- and EMT-related gene signatures associated with prognosis and the immune microenvironment in lung adenocarcinoma.

Integrative stemness- and EMT-related gene signatures associated with prognosis and the immune microenvironment in lung adenocarcinoma.

Journal: Discover oncology

Published: February 16, 2025

Retraction notice to "Sanyang Xuedai enhances the radiosensitivity of human non-small cell lung cancer cells via increasing iNOS/NO production" [Biomed. Pharmacother. 102 (2018) 618-625].

Retraction notice to "Sanyang Xuedai enhances the radiosensitivity of human non-small cell lung cancer cells via increasing iNOS/NO production" [Biomed. Pharmacother. 102 (2018) 618-625].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 10, 2024

(-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2α/ATF4 signaling pathway.

(-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2α/ATF4 signaling pathway.

Journal: PloS one

Published: April 18, 2024

miRNA-105-5p regulates the histone deacetylase HDAC2 through FOXG1 to affect the malignant biological behavior of triple-negative breast cancer cells.

miRNA-105-5p regulates the histone deacetylase HDAC2 through FOXG1 to affect the malignant biological behavior of triple-negative breast cancer cells.

Journal: The American journal of the medical sciences

Published: September 07, 2023

Combined Radiomics-Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer.

Combined Radiomics-Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer.

Journal: Technology in cancer research & treatment

Published: December 08, 2022

Low-dose aspirin can inhibit exosomal release induced by radiotherapy in breast cancer and attenuate its inhibitory effect on NK cell proliferation.

Low-dose aspirin can inhibit exosomal release induced by radiotherapy in breast cancer and attenuate its inhibitory effect on NK cell proliferation.

Journal: Cancer medicine

Published: November 28, 2022

Predictive model of spatial scale of forest fire driving factors: a case study of Yunnan Province, China.

Predictive model of spatial scale of forest fire driving factors: a case study of Yunnan Province, China.

Journal: Scientific reports

Published: June 12, 2022

Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer.

Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer.

Journal: Scientific reports

Published: January 14, 2022

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.

Journal: Therapeutic advances in medical oncology

Published: December 21, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026